Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Respir Med ; 129: 16-23, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28732825

RESUMEN

We retrospectively studied the clinical presentation, treatment modalities and outcome in 16 patients with heterozygous NKX2-1 mutation associated with chronic lung disease. Twelve different NKX2-1 mutations, including 4 novel mutations, were identified in the 16 patients. Nine patients presented with brain-lung-thyroid syndrome, 3 had neurological and lung symptoms and 4 had only pulmonary symptoms. Ten patients had neonatal respiratory distress, and 6 of them developed infiltrative lung disease (ILD). The other patients were diagnosed with ILD in childhood (n = 3) or in adulthood (n = 3). The median age at diagnosis was 36 months (IQ 3.5-95). Patient testing included HRCT (n = 13), BALF analysis (n = 6), lung biopsies (n = 3) and lung function tests (n = 6). Six patients required supplemental oxygen support with a median duration of 18 months (IQ 2.5-29). All symptomatic ILD patients (n = 12) benefited from a treatment consisting of steroids, azithromycin (n = 9), and/or hydroxychloroquine (n = 4). The median follow-up was 36 months (IQ 24-71.5). One patient died of respiratory failure at 18 months and another is waiting for lung transplantation. In summary, the initial diagnosis was based on clinical presentation and radiological features, but the presentation was heterogeneous. Definitive diagnosis required genetic analysis, which should be performed, even in absence of neurological or thyroid symptoms.


Asunto(s)
Enfermedades Pulmonares Intersticiales/genética , Enfermedades Pulmonares/genética , Enfermedades Pulmonares/patología , Proteinosis Alveolar Pulmonar/genética , Proteína B Asociada a Surfactante Pulmonar/deficiencia , Factor Nuclear Tiroideo 1/genética , Adolescente , Adulto , Atetosis/complicaciones , Atetosis/genética , Atetosis/patología , Líquido del Lavado Bronquioalveolar/química , Niño , Corea/complicaciones , Corea/genética , Corea/patología , Hipotiroidismo Congénito/complicaciones , Hipotiroidismo Congénito/genética , Hipotiroidismo Congénito/patología , Femenino , Francia/epidemiología , Genes Homeobox , Humanos , Enfermedades Pulmonares/complicaciones , Enfermedades Pulmonares/terapia , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Enfermedades Pulmonares Intersticiales/fisiopatología , Enfermedades Pulmonares Intersticiales/terapia , Masculino , Mutación , Pronóstico , Proteinosis Alveolar Pulmonar/complicaciones , Proteína B Asociada a Surfactante Pulmonar/genética , Surfactantes Pulmonares/metabolismo , Síndrome de Dificultad Respiratoria del Recién Nacido/complicaciones , Síndrome de Dificultad Respiratoria del Recién Nacido/etiología , Síndrome de Dificultad Respiratoria del Recién Nacido/genética , Síndrome de Dificultad Respiratoria del Recién Nacido/patología , Pruebas de Función Respiratoria/métodos , Estudios Retrospectivos , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
2.
Br J Pharmacol ; 173(11): 1728-41, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26894321

RESUMEN

BACKGROUND AND PURPOSE: Pulmonary disease is the main cause of morbidity and mortality in cystic fibrosis (CF) patients due to exacerbated inflammation. To date, the only anti-inflammatory drug available to CF patients is high-dose ibuprofen, which can slow pulmonary disease progression, but whose cyclooxygenase-dependent digestive adverse effects limit its clinical use. Here we have tested sulindac, another non-steroidal anti-inflammatory drug with an undefined anti-inflammatory effect in CF airway epithelial cells. EXPERIMENTAL APPROACH: Using in vitro and in vivo models, we NF-κB activity and IL-8 secretion. In HeLa-F508del cells, we performed luciferase reporter gene assays in order to measure i) IL-8 promoter activity, and ii) the activity of synthetic promoter containing NF-κB responsive elements. We quantified IL-8 secretion in airway epithelial CFBE cells cultured at an air-liquid interface and in a mouse model of CF. KEY RESULTS: Sulindac inhibited the transcriptional activity of NF-κB and decreased IL-8 transcription and secretion in TNF-α stimulated CF cells via a cyclooxygenase-independent mechanism. This effect was confirmed in vivo in a mouse model of CF induced by intra-tracheal instillation of LPS, with a significant decrease of the induction of mRNA for MIP-2, following treatment with sulindac. CONCLUSION AND IMPLICATIONS: Overall, sulindac decrease lung inflammation by a mechanism independent of cycolooxygenase. This drug could be beneficially employed in CF.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Fibrosis Quística/tratamiento farmacológico , Prostaglandina-Endoperóxido Sintasas/metabolismo , Sulindac/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Línea Celular , Fibrosis Quística/metabolismo , Células HeLa , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Sulindac/administración & dosificación
4.
Horm Res Paediatr ; 77(3): 146-51, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22488412

RESUMEN

BACKGROUND: NKX2.1 mutations have been identified in patients displaying complete or partial brain-lung-thyroid syndrome, which can include benign hereditary chorea (BHC), hypothyroidism and/or lung disease. AIMS AND METHODS: We evaluated the recently developed Multiplex Ligation-dependent Probe Amplification (MLPA) method to assess the relative copy number of genes. The goal was to determine if MLPA could improve, in addition to direct sequencing, the detection rate of NKX2.1 mutations in a phenotype-selected cohort of 24 patients affected by neurological, thyroid and/or pulmonary disorders. RESULTS: Direct sequencing revealed two heterozygous mutations. Using MLPA, we identified two further heterozygous NKX2.1 gene deletions. MLPA increased the detection rate by 50%. All patients with gene deletions identified were affected by BHC and congenital hypothyroidism. CONCLUSION: MLPA should be considered as a complementary tool in patients with partial or total brain-lung-thyroid syndrome when direct sequencing failed to identify NKX2.1 mutations. All patients with an NKX2.1 mutation had BHC and congenital hypothyroidism, emphasizing the high prevalence of these signs associated with defective NKX2.1 alleles.


Asunto(s)
Corea/genética , Hipotiroidismo Congénito/genética , Enfermedades Pulmonares/genética , Proteínas Nucleares/genética , Factores de Transcripción/genética , Niño , Preescolar , Femenino , Eliminación de Gen , Humanos , Recién Nacido , Masculino , Mutación , Técnicas de Amplificación de Ácido Nucleico/métodos , Síndrome , Factor Nuclear Tiroideo 1
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA